Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polynovo ( (AU:PNV) ) has shared an update.
PolyNovo Limited has achieved a significant commercial milestone with the Therapeutic Goods Administration (TGA) clearance of its NovoSorb MTX (4 mm and 6 mm) products in Australia. This clearance allows the products to be marketed and sold, providing healthcare professionals with versatile options for managing soft tissue defects. The NovoSorb MTX is designed to support natural wound healing, particularly for highly exudative wounds or those with uneven wound beds, and addresses clinician demand for products without a sealing membrane. This development enhances PolyNovo’s industry positioning by expanding its product offerings and meeting the needs of plastic surgeons and other healthcare providers.
More about Polynovo
PolyNovo is a disruptive medical technology company based in Melbourne, Australia, specializing in products that simplify the management of acute complex wounds. The company is known for redefining healing with differentiated patient outcomes and has treated over 70,000 patients across 46 countries. PolyNovo is focused on growth through new products, indications, and market expansion.
YTD Price Performance: -28.19%
Average Trading Volume: 3,086,934
Technical Sentiment Signal: Sell
Current Market Cap: A$1.01B
See more insights into PNV stock on TipRanks’ Stock Analysis page.